Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

TB R&D Update: Researchers at EPFL create organization to help bring promising new antibiotic, ‘PBTZ169’, to market

PBTZ169

Researchers at EPFL and the Bach Institute in Moscow have discovered an antibiotic effective against sensitive and MDR-tuberculosis. With support from EPFL, the researchers have created Innovative Medicines for Tuberculosis (iM4TB), an organization to help usher the new antibiotic to market.

Sirturo (bedaquiline) approved for conditional use in European Union to treat MDR-TB in adults

Sirturo

The European Medicines Agency has recently approved Sirturo for conditional use in the European Union. A link to the press release is included.

TB R&D Update: Semisynthetic antibiotic effective against sensitive and drug resistant tuberculosis in vitro

St Judes

This week we highlight a study by Richard E. Lee et al showing that semisynthetic antibiotic, spectinamides, is effective against drug sensitive and resistant tuberculosis. Additional links related to this study and general TB R&D are included.

26 Nov 2013

EMA Reverses Opinion on Delamanid for MDR-TB

otsuka

A European Union panel has recommended regulatory approval of a tuberculosis drug that would become only the second major new antibiotic against the deadly disease in more than 40 years.

25 Oct 2013

WHO Global TB Report 2013: Slow decline in Disease Burden, New Tools Needed to Reach Goals

GTBR13_cover M inhouse

This is the eighteenth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress made to date. Additional links to news coverage of the report are included

30 Jul 2013

EMA fails to recommend Otsuka’s Delamanid for MDR TB

otsuka

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) failed to recommend marketing approval for delamanid, a new drug in development for multidrug-resistant tuberculosis (MDR-TB). A letter from the Treatment Action Group criticizing this decision is included.

10 Jul 2013
by Working Group

Posted in Faces of TB, TB Drug Development, TB News

How to Combat Tuberculosis: NPR Highlights

npr

Yesterday, the US National Public Radio posted online two insightful pieces on tuberculosis: 1) What It Takes To Cure Drug-Resistant Tuberculosis 2) Treating The ‘Body And Soul’ In A Russian TB Prison

9 Jul 2013
by Working Group

Posted in Announcements, TB Drug Development, TB News

Otsuka Begins Paediatric MDR-TB Trials

otsuka

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB). Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a dispersible formulation for use with younger children and infants.

1 Jul 2013
by Working Group

Posted in Action, TB Drug Development, TB News

TAG Releases 2013 Pipeline Report

Click here to access full report

HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

13 Jun 2013

WHO Issues Interim Guidance on the Use of Bedaquiline to Treat

who-logo

The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB).